FindTrial
Sign In

A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection

A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002270
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Leukoencephalopathy, Progressive Multifocal

Keywords

Leukoencephalopathy, Progressive Multifocal, Interferon Alfa-2b, Drug Evaluation, Acquired Immunodeficiency Syndrome, Zidovudine

Brief summary

To study the effectiveness of alpha interferon (IFN-A2b) and zidovudine (AZT) in treating progressive multifocal leukoencephalopathy (PML) as a complication of HIV-1 infection.

Interventions

DRUGInterferon alfa-2b
DRUGZidovudine

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Patients must have: * HIV seropositivity by both ELISA and Western blot. * Biopsy proven progressive multifocal leukoencephalopathy (PML).

Exclusion criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Intolerant to interferon. * Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis, multiple sclerosis (MS), or neurosyphilis. Patients with the following are excluded: * Intolerant to interferon. * Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis, multiple sclerosis (MS), or neurosyphilis. Prior Medication: Excluded: * Patients receiving interferon for other reasons.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026